<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/E8EE1BC9-799D-4921-8C12-8689B9552A74"><gtr:id>E8EE1BC9-799D-4921-8C12-8689B9552A74</gtr:id><gtr:firstName>Jon</gtr:firstName><gtr:surname>Frampton</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_PC_12011"><gtr:id>089A0A37-0A7C-49CC-8F7D-D1516DBEAE79</gtr:id><gtr:title>Confidence in Concept 2012 - University of Birmingham</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_PC_12011</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>The Confidence in Concept scheme is a key part of MRC?s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach ?? before seeking more substantive funding.&amp;nbsp; It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.</gtr:technicalSummary><gtr:fund><gtr:end>2014-02-01</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-08-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>600000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1300000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>European Industrial Doctorate</gtr:description><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>5B6950ED-0104-492F-806F-761E7530919F</gtr:id><gtr:outcomeId>546b0be30d2e29.41015954</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>308000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Biomedical Research Centre</gtr:department><gtr:description>NIHR (Dr John Campbell, CiC: Unique multiplexed assays to identify and measure monoclonal immunoglobulin (Mig) for the diagnosis and management of plasma cell dyscrasias (PCDs); optimisation and clinical validation of laboratory-based assays)</gtr:description><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>5C66A2D1-AD3D-4D26-9CEC-0F35B4E4EEA6</gtr:id><gtr:outcomeId>56dee81a2baad5.03266404</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>322664</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>KKLF (Dr Farhat Khanim, CiC: A pharmacological database for enabling implementation of Accelerated Drug Redeployment Programme (ADReP))</gtr:description><gtr:fundingOrg>The Kay Kendall Leukaemia Fund (KKLF)</gtr:fundingOrg><gtr:id>557F5BB3-0CE7-4EF4-B0EB-E083EBFC9066</gtr:id><gtr:outcomeId>56dee909b86b01.02844742</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1297366</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Programme Grant</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>Leukaemia and Lymphoma Research</gtr:fundingOrg><gtr:id>D8AA3158-9ED4-4D45-9562-857D7148D5C7</gtr:id><gtr:outcomeId>5461e737135914.97467845</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Enterprise Fellowship (joint with BBSRC)</gtr:description><gtr:end>2015-08-02</gtr:end><gtr:fundingOrg>Royal Society of Edinburgh (RSE)</gtr:fundingOrg><gtr:id>A1742F21-01AB-4593-8E59-24A6DD153AB7</gtr:id><gtr:outcomeId>5461e4961a9745.65421992</gtr:outcomeId><gtr:sector>Learned Society</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>25000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>WT ISSF (Dr Dagmar Scheel-Toellner, CiC: Can FcRL-4 expression by B cells be used as a biomarker for the early diagnosis of rheumatoid arthritis)</gtr:description><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>1305D592-9595-4B2A-86B9-983270648B81</gtr:id><gtr:outcomeId>56deebd123aa71.76845970</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1297366</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>LLR (Dr Farhat Khanim, CiC: A pharmacological database for enabling implementation of Accelerated Drug Redeployment Programme (ADReP))</gtr:description><gtr:fundingOrg>Leukaemia and Lymphoma Research</gtr:fundingOrg><gtr:id>B57E3BD6-7CD1-4BB7-A7BB-2F994B6F9EE4</gtr:id><gtr:outcomeId>56dee8a2d35249.20439864</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>149014</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Pathfinder Grant (Professor Ed Rainger, CiC: Characterising the endothelial cell receptor for PEPITEM, a novel peptide that regulates T-cell trafficking during inflammation)</gtr:description><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>B4658A43-B146-4AB3-8D40-19AC46BD7E63</gtr:id><gtr:outcomeId>56deea0eaa5989.55630343</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1500000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>EU VAMPIRE (Professor Roy Bicknell post Validation of Novel Lung Tumour Endothelial Targets CiC)</gtr:description><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>4A1B7219-57A5-47A4-B869-CBA01981CE51</gtr:id><gtr:outcomeId>56dee77a0e5191.78233720</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>591634</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC DPFS (Dr Dagmar Scheel-Toellner, CiC: Can FcRL-4 expression by B cells be used as a biomarker for the early diagnosis of rheumatoid arthritis)</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>2169F12E-4D7D-45F2-B018-158B443ABB05</gtr:id><gtr:outcomeId>56deeb57374db3.66089739</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC/RSE Fellowship (Dr Mark Cobbold, CiC: Advancing a generic scalable chromatography separation device for human therapeutic cells)</gtr:description><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>5A24069A-2883-49B9-9AB2-BC45F3B43265</gtr:id><gtr:outcomeId>56deeceb2f9fe2.83577071</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>591634</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Developmental Pathway Funding Scheme</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/M007669/1</gtr:fundingRef><gtr:id>556FBE41-A0BF-4D33-B729-4EF466137A3D</gtr:id><gtr:outcomeId>5461e3aaeba3c4.40742995</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>12000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Royal Society international exchange Shanghai (Dr Daniel Tennant, CiC: Validation of a novel means of stratifying patients with low grade glioma by survival)</gtr:description><gtr:fundingOrg>The Royal Society</gtr:fundingOrg><gtr:id>0E7D80C2-4323-4C38-911A-94E8A1BFE3E4</gtr:id><gtr:outcomeId>56deec551e6e53.30420693</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>CDH15 has been identified as a receptor for a peptide which has an inhibitory effect of the migration of T cells. Agonists of this receptor have applications in the treatment and/or prophylaxis of conditions associated with the migration of T-cells, including T cell auto-reactivity, T cell mediated chronic inflammatory disease and autoimmune disease. The agonist is not PEPITEM or an analogue thereof.</gtr:description><gtr:grantRef>MC_PC_12011</gtr:grantRef><gtr:id>65A4A0DE-0B8C-4E3D-843D-E80EEB63E92F</gtr:id><gtr:impact>Many collaborations and discussions.</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:outcomeId>56def27b791392.22420750</gtr:outcomeId><gtr:patentId>GB201312010 (Prof Ed Rainger)</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>CADHERIN 15 AGONISTS</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>A radio-or chemo-sensitising compound comprising a nanoparticle and attached to the nanoparticle; (i) a DNA repair inhibitor; and (ii) a nuclear localisation signal element (NLS); optionally attached via one or more linker moieties.</gtr:description><gtr:grantRef>MC_PC_12011</gtr:grantRef><gtr:id>6C4A539C-C8F2-4521-BFF6-A9658F0661B7</gtr:id><gtr:impact>Multiple collaborations and discussions.</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:outcomeId>56defef67af920.91711494</gtr:outcomeId><gtr:patentId>GB201209517 (Dr Boris Kysela)</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>NANOPARTICLES WITH ATTACHED DNA REPAIR INHIBITORS AND NUCLEAR LOCALISATION SIGNAL ELEMENTS</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The present invention relates to methods and uses of FcRL4 expression and optionally RANKL expressing B cells as biomarkers and therapeutic target for treatment of an autoimmune and/or chronic diseases associated with joint inflammation, in particular Rheumatoid Arthritis (RA).</gtr:description><gtr:grantRef>MC_PC_12011</gtr:grantRef><gtr:id>76AF8760-5190-4F95-AAB9-68B25CA339B0</gtr:id><gtr:impact>MRC DPFS funding secured to continue work on this project, commencing in Oct 2014. Discussions with Kymab Access around RA and Sj&amp;ouml;gren's syndrome work ongoing.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>5461eb612a91c8.56908632</gtr:outcomeId><gtr:patentId>WO2014118550</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>BIOMARKERS OF AUTOIMMUNE AND/OR CHRONIC DISEASES ASSOCIATED WITH JOINT INFLAMMATION</gtr:title></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The present invention relates to methods and uses of FcRL4 expression and optionally RANKL expressing B cells as biomarkers and therapeutic target for treatment of an autoimmune and/or chronic diseases associated with joint inflammation, in particular Rheumatoid Arthritis (RA).</gtr:description><gtr:grantRef>MC_PC_12011</gtr:grantRef><gtr:id>8775C1B1-8878-4F19-8174-D17DD091BC17</gtr:id><gtr:impact>Collaborations and discussions. EPO: 14702926.8-1408 (2015) USPO:141764671 (2015)</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:outcomeId>56defb6e2ba873.27649074</gtr:outcomeId><gtr:patentId>GB201301708 (Dr Dagmar Scheel-Toellner)</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>BIOMARKERS OF AUTOIMMUNE AND/OR CHRONIC DISEASES ASSOCIATED WITH JOINT INFLAMMATION</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Design and preclinical testing of a cancer specific conjugate vaccine</gtr:description><gtr:grantRef>MC_PC_12011</gtr:grantRef><gtr:id>ACFD391D-6360-44C8-9F16-0560D8CF40B4</gtr:id><gtr:impact>GB1320421.9, Priority Date: 19/11/2013 GB1419061.5 (2014)</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:outcomeId>56df027207fbc8.19901003</gtr:outcomeId><gtr:patentId>GB1419061.5 (Dr Kai Toellner)</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Conjugated Vaccine</gtr:title><gtr:yearProtectionGranted>2014</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Provided is a method for treatment and/or prophylaxis of a condition associated with T cell mediated chronic inflammatory disease by administration, to a patient, of a peptide comprising N'-SVTEQGAELSNEER-C' {SEQ ID NO: 1) or an analogue thereof that inhibits T cell migration. Also provided is the peptide or its analogue for use in the methods of treatment: and/or prophylaxis of said condition.</gtr:description><gtr:grantRef>MC_PC_12011</gtr:grantRef><gtr:id>225AB3A2-86F9-423C-B4DC-3F55D48FCA63</gtr:id><gtr:impact>EP2802342, Priority Date: 13/01/2012</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:outcomeId>58c9783fa6cee6.01504824</gtr:outcomeId><gtr:patentId>WO2013104928 (Prof. Ed Rainger)</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>PEPTIDE AND USES THEREOF</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The present invention relates generally to genes and polypeptides which are differentially expressed in tumour vasculature, as compared to normal tissue vasculature, to the use of antibodies that bind these polypeptides for imaging and targeting tumour vasculature, and to the use of inhibitors of these tumour vasculature expressed genes/polypeptides for inhibiting vasculature, such as angiogenesis in solid tumours. In particular, the present invention relates to tumour endothelial markers (TEMs), to the use of antibodies that bind such TEMs for imaging and targeting tumour vasculature, and to the use of inhibitors of such TEMs for inhibiting vasculature such as angiogenesis in solid tumours. In a preferred embodiment the TEM is PCDH7.</gtr:description><gtr:grantRef>MC_PC_12011</gtr:grantRef><gtr:id>D5A0CC1A-3688-4D79-BB6E-4DAC948EFDE2</gtr:id><gtr:impact>GB20140021900, Prioirty date: 9/12/2014</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:outcomeId>58c976eb00acc9.97750203</gtr:outcomeId><gtr:patentId>WO2016092301 (Prof Roy Bicknell)</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Vascular Targeting</gtr:title><gtr:yearProtectionGranted>2016</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>A radio-or chemo-sensitising compound comprising a nanoparticle and attached to the nanoparticle; (i) a DNA repair inhibitor; and (ii) a nuclear localisation signal element (NLS); optionally attached via one or more linker moieties.</gtr:description><gtr:grantRef>MC_PC_12011</gtr:grantRef><gtr:id>A916D2B9-0446-4799-8B5B-B8B558EDFC6E</gtr:id><gtr:impact>Consultations in progress with two potential industrial partners, Heraeus Precious Metals GmbH in Germany and Novobiotix in the US. MRC DPFS and Novartis Research Foundation applications in preparation with clinical specialists from QE Medical Physics and Radiotherapy Departments</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>5461ee9b271de9.99445519</gtr:outcomeId><gtr:patentId>WO2013179014</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>NANOPARTICLES WITH ATTACHED DNA REPAIR INHIBITORS AND NUCLEAR LOCALISATION SIGNAL ELEMENTS</gtr:title></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>A custom-built in-house drug redeployment library (based on three freely available pharmacological databases) to be used as part of the investigators' Accelerated Drug Redeployment Program (ADReP) with the goal of identifying new combination therapies for haematological malignancies.</gtr:description><gtr:id>8A6658A6-F1FB-4CC5-87D6-61F6EC02B69F</gtr:id><gtr:impact>An application was made to the MRC DPFS, &amp;quot;From Bench to Bedside in 3 years: A novel translational drug redeployment programme (ADReP) for Multiple Myeloma and B cell Non-Hodgkin's Lymphoma&amp;quot;, reaching the final funding review meeting in July 2013, however this was unsuccessful at the last stage. Feedback from the panel was however positive with scores of 5 (excellent). The comments will be used to help strengthen a new application that will be submitted to Leukaemia &amp;amp; Lymphoma Research in 2015. Further applications have been made to LLR (2 year project grant) and Kay Kendall Leukaemia Fund (3 year project grant). We will be notified of the outcome of these grants in November 2014. Prof. Dion Morton (UoB) has allocated funding for a two-year Post-Doctoral contract to work on solid tumours using this database and methodology. We are in discussions with Alta Innovations, UoB's IP and commercialisation company regarding the commercial potential of the database.</gtr:impact><gtr:outcomeId>5461e97b7d1722.78746430</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Drug redeployment library</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>An algorithm to stratify patients with low grade gliomas in order to identify those patients for whom early therapeutic intervention would improve their long-term survival. Using the data we were able to successfully stratify patients with low grade gliomas in the three clusters previously identified, thereby validating this approach. We also used the results to confirm that this stratification is not dependent on previously identified stratification markers, and have identified a completely novel point mutation in another metabolic enzyme that also stratifies patients.</gtr:description><gtr:id>1D299F29-375A-40C9-B323-F4325D8E5E89</gtr:id><gtr:impact>After discussions with external collaborators, we plan to submit a paper to Nature Genetics based on the significant dataset generated in the project. A patent application is in preparation and will be filed before the end of 2014. Parallel analyses have already uncovered a novel enzyme mutation that appears to stratify patients. These preliminary data will be used along with other expression data from the original dataset to apply for CRUK and further MRC funding in 2014/15.</gtr:impact><gtr:outcomeId>5461ecae87a8c7.21789789</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Low grade glioma survival stratification model</gtr:title><gtr:type>Computer model/algorithm</gtr:type></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Serascience Ltd</gtr:companyName><gtr:description>Serascience Limited is a specialist cancer diagnostic company established in April 2011 to develop medical devices for the diagnosis and management of patients with myeloma and related disorders, collectively known as B-cell dyscrasias. Our innovative products will improve patient management through better diagnostic and prognostic assessment.
Serascience supply a broad range of class and subclass specific anti immunoglobulin antibodies, for research use. We offer unique, highly specific, quality antibodies at a competitive price. Our catalogue includes monoclonal antibodies for all immunoglobulins classes, and a number of subclasses, as well as antibodies to the heavy and light chains of immunoglobulins. These antibodies can be used for an array of applications and assays, such as WB (Western blots), ELISAs (Enzyme-linked immunosorbent assays), IP (Immuneprecipitation), IHC (Immunohistochemistry), ICC (Immunocytochemistry), and flow cytometry.</gtr:description><gtr:id>554ECF6A-1957-46D5-BEFD-F5E7527D9922</gtr:id><gtr:impact>In Oct 2014, Abingdon Health, the specialist rapid diagnostic technology company, announced the acquisition of Serascience Limited and the completion of group fund-raising of &amp;pound;2.1m from current shareholders. The acquisition represents a further development in Abingdon Health's strategy to create a leading innovative global diagnostic company. This follows on from a project joint funded by CiC and Serascience, and a move by the postdoc working on this project, from UoB to Serascience.</gtr:impact><gtr:outcomeId>5461f220a55917.20939529</gtr:outcomeId><gtr:yearCompanyFormed>2011</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>56BC8EBA-FE1C-4C2E-A1C6-0B80033557CD</gtr:id><gtr:title>Homeostatic regulation of T cell trafficking by a B cell-derived peptide is impaired in autoimmune and chronic inflammatory disease.</gtr:title><gtr:parentPublicationTitle>Nature medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0ac0822fe925fdd1d749368b83a0d1ed"><gtr:id>0ac0822fe925fdd1d749368b83a0d1ed</gtr:id><gtr:otherNames>Chimen M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1078-8956</gtr:issn><gtr:outcomeId>58b6f0ce3e49a4.48664883</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CBD90EA8-3723-4F6A-B971-CF493E338B6F</gtr:id><gtr:title>Rheumatoid arthritis: Are FcRL4+ B cells the next target for RA biologic therapy?</gtr:title><gtr:parentPublicationTitle>Nature reviews. Rheumatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb142cfcfb4fa7444a99cd770cdb7cb1"><gtr:id>fb142cfcfb4fa7444a99cd770cdb7cb1</gtr:id><gtr:otherNames>Bernard NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1759-4790</gtr:issn><gtr:outcomeId>58b6f119b86423.29254314</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>93D38310-4028-46FF-BD9E-ADCEAC8EFBA7</gtr:id><gtr:title>Identification of novel vascular targets in lung cancer.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ddae1f84248950d6c76160736b6de5e"><gtr:id>4ddae1f84248950d6c76160736b6de5e</gtr:id><gtr:otherNames>Zhuang X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>58b6f09ebfdfe9.33175758</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D7657DF1-4214-475C-80CF-DD2F3D287D26</gtr:id><gtr:title>Release of Active Peptidyl Arginine Deiminases by Neutrophils Can Explain Production of Extracellular Citrullinated Autoantigens in Rheumatoid Arthritis Synovial Fluid.</gtr:title><gtr:parentPublicationTitle>Arthritis &amp; rheumatology (Hoboken, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/af7c81acf46d1d62d445108ce1fc0164"><gtr:id>af7c81acf46d1d62d445108ce1fc0164</gtr:id><gtr:otherNames>Spengler J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2326-5191</gtr:issn><gtr:outcomeId>585d57e2065a90.13451319</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EFFF9663-1FCD-41EF-9B0C-CD76863B9638</gtr:id><gtr:title>Robo4 vaccines induce antibodies that retard tumor growth.</gtr:title><gtr:parentPublicationTitle>Angiogenesis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ddae1f84248950d6c76160736b6de5e"><gtr:id>4ddae1f84248950d6c76160736b6de5e</gtr:id><gtr:otherNames>Zhuang X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0969-6970</gtr:issn><gtr:outcomeId>5461e25dc124b2.98033759</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>28675EB2-4AC4-41FA-9148-AA9C5C7533A9</gtr:id><gtr:title>Expression of FcRL4 defines a pro-inflammatory, RANKL-producing B cell subset in rheumatoid arthritis.</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/704de06b92958737d590589fed939747"><gtr:id>704de06b92958737d590589fed939747</gtr:id><gtr:otherNames>Yeo L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>5461e1949456a3.88851287</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_PC_12011</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C4255A20-7C03-4147-BA26-8D72C9457F1C</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Health Uncodeable</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>06E85C67-BEDD-4C93-990D-B74FCF876924</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Research Uncodeable</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>